Content Block Tag: NRG-GY003
‘NRG-GY003 Documentation’ of page ‘NRG-GY003’
Reactivation and Amendment 5 documents (posted 5/22/17) Summary: CTSU information updated; PMB information updated; Translational Research information updated; Statistical section provides further information about possibility of amending to a single-arm study if the conbination regimen proves uninteresting; if a patient has radiologic-determined progression at the first 8-week CT, the 8-week CT will serve as the […]
Read More
‘NRG-GY003: A Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer’ of page ‘NRG-GY003’
Principal Investigator/Co-Principal Investigator Robert A. Burger, M.D./Carol Aghajanian, M.D. Primary Objectives To estimate the proportion of patients who have objective tumor response (complete or partial) by modified RECIST 1.1 in patients with persistent or recurrent epithelial ovarian, fallopian tube, primary peritoneal cancers, treated with nivolumab or the combination of nivolumab and ipilimumab and to assess […]
Read More